Credit Suisse’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Credit Suisse’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-338,300	Closed	-$37.9M	–	4397
2021 Q4	$37.9M	Buy	338,300 +198,300	+142%	+$23.9M	0.02%	772
2021 Q3	$17.6M	Sell	140,000 -65,600	-32%	-$8.45M	0.01%	1154
2021 Q2	$27.8M	Buy	205,600 +39,400	+24%	+$5.18M	0.01%	981
2021 Q1	$22.5M	Buy	166,200 +87,300	+111%	+$13.1M	0.01%	1104
2020 Q4	$11.1M	Buy	78,900 +19,500	+33%	+$2.5M	0.01%	1510
2020 Q3	$6.62M	Buy	59,400 +9,400	+19%	+$1.05M	﹤0.01%	1618
2020 Q2	$5.6M	Sell	50,000 -50,000	-50%	-$4.92M	﹤0.01%	1638
2020 Q1	$7.74M	Buy	100,000 +39,200	+64%	+$3.47M	0.01%	1300
2019 Q4	$5.78M	Hold	60,800	–	–	﹤0.01%	1780
2019 Q3	$4.64M	Buy	60,800 +3,700	+6%	+$307K	﹤0.01%	1813
2019 Q2	$5.01M	Buy	57,100 +6,100	+12%	+$520K	﹤0.01%	1755
2019 Q1	$4.62M	Sell	51,000 -170,300	-77%	-$14.5M	﹤0.01%	1768
2018 Q4	$15.9M	Buy	221,300 +171,300	+343%	+$13.8M	0.02%	915
2018 Q3	$4.79M	Sell	50,000 -400,000	-89%	-$38.8M	﹤0.01%	1719
2018 Q2	$42.8M	Buy	+450,000	New	+$41.4M	0.04%	446
2018 Q1	–	Sell	-90,000	Closed	-$7.64M	–	4172
2017 Q4	$7.64M	Buy	+90,000	New	+$7.54M	0.01%	1460

Other funds holding XBI

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Credit Suisse's XBI Position: Q1 2024 in Review

Credit Suisse reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 91% in Q1 2024, selling an estimated $21.1M and leaving 23,460 shares worth $2.23M. The position accounts for ﹤0.01% of the portfolio, ranked #1778.

Credit Suisse first reported a position in XBI in Q2 2013 and has held it in 44 quarters since. The position peaked at $124M in Q3 2015. 780 funds tracked by Wall St. Rank hold XBI as of Q1 2024.

Credit Suisse held 23,460 shares of State Street SPDR S&P Biotech ETF worth $2.23M as of Q1 2024.
Credit Suisse sold 227,868 State Street SPDR S&P Biotech ETF shares in Q1 2024, an estimated $21.1M.
State Street SPDR S&P Biotech ETF made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #1778 holding.
Credit Suisse first reported a position in State Street SPDR S&P Biotech ETF in Q2 2013 and has held it in 44 quarters since.
Credit Suisse's State Street SPDR S&P Biotech ETF position peaked at $124M in Q3 2015.
780 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.